
Pfizer enters $5 billion share buyback deal with Goldman Sachs
pharmafile | March 9, 2016 | News story | Business Services, Research and Development | Pfizer, Share buyback, Stock, markets
US drug major Pfizer (NYSE: PFE) on Wednesday said it has entered into an accelerated share repurchase agreement with Goldman, Sachs & Co to repurchase $5 billion of the company’s stock. This agreement is part of Pfizer’s existing share repurchase authorization.
Pfizer will receive about 136 million shares following the transaction on March 10, 2016. At settlement of the agreement, which is expected to occur during the second quarter of 2016, Goldman, Sachs & Co may be required to deliver additional shares of common stock to Pfizer.
Anjali Shukla
Related Content
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …

Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …






